Hexarelin

Overview

Hexarelin (also known as examorelin) is a synthetic hexapeptide growth hormone-releasing peptide (GHRP) that acts through the growth hormone secretagogue receptor (GHS-R1a), the same receptor activated by the endogenous hormone ghrelin. Among the GHRP family, hexarelin is generally considered the most potent in terms of acute growth hormone release, producing robust GH elevation that exceeds other members of its class including GHRP-6 and GHRP-2.

First developed by researchers at the University of Milan in the early 1990s, hexarelin has been the subject of considerable clinical research, particularly in endocrinology and cardiology. Its most distinctive characteristic beyond GH release is its documented cardiac effects, including direct cardioprotective actions that appear to be at least partially independent of GH/IGF-1 elevation.

Structure and Properties

Amino Acid Sequence

His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2

• Molecular weight: 887.04 g/mol
• Molecular formula: C47H58N12O6
• Length: 6 amino acids (hexapeptide)
• Notable features: Contains two D-amino acids (D-2-methyl-tryptophan and D-phenylalanine) and a C-terminal amide, conferring resistance to enzymatic degradation

The inclusion of D-amino acids and the methylated tryptophan distinguish hexarelin from the native substrate and provide significantly improved metabolic stability compared to endogenous GH-releasing factors.

Physical Properties

• White to off-white lyophilized powder
• Soluble in water and bacteriostatic water
• Stored at -20 C for long-term stability
• Estimated half-life of approximately 60-70 minutes

Mechanism of Action

GH Secretagogue Receptor (GHS-R1a)

Hexarelin's primary mechanism involves binding to the GHS-R1a receptor on anterior pituitary somatotroph cells. This receptor activation triggers an intracellular signaling cascade involving:

• Phospholipase C activation
• Inositol trisphosphate (IP3) production
• Intracellular calcium mobilization
• GH granule exocytosis

This pathway is distinct from and complementary to the GHRH receptor pathway, which is why GHRPs and GHRH analogs produce synergistic GH release when combined.

Somatostatin Interaction

Hexarelin appears to functionally antagonize somatostatin's inhibitory effects on GH release. Rather than blocking somatostatin receptors directly, hexarelin's signaling cascade overrides somatostatin-mediated suppression of calcium influx in somatotrophs.

Direct Cardiac Effects

Hexarelin binds to a specific cardiac receptor population that includes GHS-R1a expressed in cardiac tissue and possibly additional, not yet fully characterized binding sites. Cardiac effects include:

• Protection against ischemia-reperfusion injury (cardioprotection)
• Reduction in cardiac fibrosis
• Anti-apoptotic effects in cardiomyocytes
• Modulation of calcium handling in cardiac cells
• Effects on cardiac mitochondrial function

Importantly, some of these cardiac effects have been demonstrated in GH-deficient models, suggesting they are at least partially independent of GH elevation.

Additional Receptor Interactions

Unlike more selective GHRPs such as ipamorelin, hexarelin also stimulates:

• Cortisol release — Through ACTH stimulation (modest but measurable)
• Prolactin release — Via hypothalamic dopaminergic modulation
• These secondary hormonal effects contribute to hexarelin's profile as one of the less "clean" GHRPs

Clinical Research

GH Release Studies

Hexarelin has been extensively studied in human subjects for its GH-releasing capacity:

• Single-dose studies: Intravenous hexarelin (1-2 mcg/kg) produces GH peaks of 40-80 ng/mL in healthy young adults — among the highest GH responses reported for any secretagogue
• Dose-response: The dose-response curve plateaus at approximately 2 mcg/kg, with no additional benefit at higher doses
• Age effects: GH response to hexarelin declines with age but remains measurable in elderly subjects, unlike some other provocative stimuli
• Diagnostic use: Hexarelin has been studied as a GH provocation test for diagnosing GH deficiency, with sensitivity comparable to established tests

Tachyphylaxis (Desensitization)

A critical finding in hexarelin research is the development of tachyphylaxis — a diminished GH response with repeated administration:

• Acute desensitization: GH response decreases significantly after continuous or twice-daily administration over 4-16 weeks
• Partial recovery: The response partially recovers after a washout period
• Mechanism: Likely involves GHS-R1a receptor downregulation and/or enhanced somatostatin tone
• Clinical implications: This limits hexarelin's utility for sustained GH elevation and suggests pulsatile or intermittent dosing strategies may be preferable

This tachyphylaxis is more pronounced with hexarelin than with less potent GHRPs, possibly because its extreme potency drives more aggressive receptor desensitization.

Cardiac Research

Hexarelin's cardiac effects have been investigated in clinical and preclinical settings:

• Ischemic cardioprotection: In animal models, hexarelin administered before or during ischemia reduced infarct size, improved contractile recovery, and reduced cardiac enzyme release
• Heart failure: Improved cardiac output and reduced systemic vascular resistance in patients with severe heart failure following acute IV administration
• Post-MI remodeling: Animal data suggests reduction in adverse left ventricular remodeling following myocardial infarction
• Endothelial function: Improved flow-mediated dilation in some clinical studies, suggesting vascular protective effects

GH-Independent Cardiac Mechanisms

Research distinguishing hexarelin's cardiac effects from GH-mediated effects includes:

• Studies in hypophysectomized rats (no pituitary GH) showing preserved cardioprotection
• Cardiac effects observed at doses below the GH-releasing threshold
• Identification of cardiac GHS-R1a expression independent of pituitary receptors
• Evidence for direct mitochondrial stabilization in cardiomyocytes

Comparison with Other GHRPs

Parameter	Hexarelin	GHRP-2	GHRP-6	Ipamorelin
GH release potency	Highest	High	Moderate	Moderate
Cortisol stimulation	Moderate	Mild	Mild	Minimal
Prolactin stimulation	Moderate	Mild	Mild	Minimal
Appetite stimulation	Mild	Mild	Strong	Minimal
Tachyphylaxis	Most pronounced	Moderate	Moderate	Less pronounced
Cardiac effects	Well-documented	Limited data	Some data	Limited data
Selectivity	Low	Moderate	Low	Highest

Hexarelin's position as the most potent GHRP comes at the cost of broader hormonal effects and more pronounced desensitization compared to more selective alternatives.

Pharmacokinetics

• Administration: Subcutaneous or intravenous injection in clinical studies
• Onset of GH release: 15-30 minutes following subcutaneous injection
• Peak GH levels: 30-60 minutes post-injection
• Duration of GH elevation: Approximately 4-6 hours
• Half-life: Approximately 60-70 minutes
• Bioavailability: Not orally bioavailable; subcutaneous bioavailability estimated at 70-80%

Research Dosing in Published Literature

Clinical studies have typically employed:

• GH provocation testing: 1-2 mcg/kg intravenously
• Repeated dosing studies: 1-2 mcg/kg subcutaneously, two to three times daily
• Cardiac studies: Variable, often 1 mcg/kg intravenously

Higher doses do not proportionally increase GH release due to the ceiling effect at the dose-response curve plateau.

Safety Profile from Clinical Studies

Reported adverse effects in clinical trials include:

• Flushing and warmth at the injection site (common, transient)
• Mild increases in cortisol and prolactin (dose-dependent)
• Transient hunger sensation (less than with GHRP-6)
• Occasional dizziness
• Mild fluid retention at higher doses
• No serious adverse events reported in published clinical studies at therapeutic doses

Long-term safety data beyond several months of administration is not available.

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Dosing Schedule

Phase	Dose	Frequency	Duration
Starting	100 mcg	2-3x daily, fasted	Weeks 1-2
Target	200 mcg	2-3x daily, fasted	Weeks 3-8

Cycle Guidelines

• Cycle length: 8-12 weeks on, followed by an equal off period
• Route: Subcutaneous injection
• Timing: Administer fasted (at least 2 hours after meals, 30 minutes before eating)
• Pairing: Often combined with a GHRH peptide (e.g., CJC-1295 no DAC or Sermorelin) for synergistic GH release
• Injection sites: Rotate between abdomen, thighs, and upper arms
• Note: Hexarelin is the most potent GHRP for GH release but carries a higher tachyphylaxis risk with prolonged continuous use; cycling is strongly recommended

Current Status

Hexarelin has not received FDA or EMA approval for any indication. It remains a research compound studied primarily in academic settings. Its clinical development has been limited by the tachyphylaxis issue, which undermines the sustained GH elevation needed for most potential therapeutic applications. However, its cardiac effects continue to attract research interest as they may be achievable at doses below the GH-releasing threshold, potentially avoiding the desensitization problem.

The compound serves as an important research tool for understanding GHS-R1a biology and the relationship between growth hormone secretagogues and cardiac function.